title: Endothelin as a therapeutic target in the treatment of cardiovascular disease.
abstract: Endothelins, a family of peptides derived from the vascular endothelium and smooth muscle cells possess vasoconstrictor and mitogenic properties. By acting predominantly in a paracrine fashion, these peptides activate specific receptors and have protean effects in normal and diseased organ systems. The wide distribution of these receptors in various tissues mediate the multiplicity of physiologic actions attributed to endothelins. Much of our understanding about endothelins has come from the development of an array of receptor-specific and mixed receptor antagonists. Based on the promising results from animal studies, active research and drug development programs are under way to investigate the clinical potential of endothelin antagonism for treatment of cardiovascular disease.
authors.affiliation: Division of General Internal Medicine, New York Medical College/Westchester Medical Center, Valhalla 10595, USA.
authors.forename: S
authors.initials: S
authors.lastname: Kaur
authors.forename: W H
authors.initials: WH
authors.lastname: Frishman
authors.forename: I
authors.initials: I
authors.lastname: Singh
authors.forename: P
authors.initials: P
authors.lastname: Tamirisa
authors.forename: A
authors.initials: A
authors.lastname: Kumar
mesh_terms: D000818:Animals; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000378:metabolism* / Q000503:physiopathology; D065128:Endothelin Receptor Antagonists; D016232:Endothelins / Q000037:antagonists & inhibitors / Q000378:metabolism* / Q000627:therapeutic use*; D004730:Endothelium, Vascular / Q000187:drug effects / Q000503:physiopathology; D006801:Humans; D017466:Receptors, Endothelin / Q000627:therapeutic use; D016896:Treatment Outcome; D014662:Vasoconstrictor Agents / Q000037:antagonists & inhibitors / Q000627:therapeutic use
chemical_list: D065128:Endothelin Receptor Antagonists; D016232:Endothelins; D017466:Receptors, Endothelin; D014662:Vasoconstrictor Agents